Theralase(R) 1Q2025 Financial Statements
Theralase® will be hosting a conference call on Monday June 9 th, 2025 at 11:00 am ET, which will include a presentation of the financial and operational results for the fiscal quarter ending March 31 st, 2025.
Questions are welcome; however, to ensure we have time to review and properly address them during the call, please send them in advance to [email protected].
An archived version will be available on the website following the conference call.
Financial Summary:
For the three-month period ended March 31 st:
[ This image cannot be displayed. Please visit the source: https://images.newsfilecorp.com/files/2786/253913_18d14c9a14378a83_001.jpg ]
1 Other represents foreign exchange, interest accretion on lease liabilities and / or interest income
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/2786/253913_18d14c9a14378a83_001full.jpg
Financial Highlights
For the three-month period ended March 31, 2025:
Operational Highlights
Private Placements
The Company has raised approximately $CAN 6.3 million over the last 2 years through non-brokered private placements in support of its research and development programs. It is currently investigating the use of a full-service investment bank in the United States to advise on potential financings and US listing opportunities. Information on any future financings will be released once available in accordance with applicable securities laws.
Herpes Simplex Virus ('HSV') Treatment Program
Theralase® continues preclinical development of its HSV treatment using non-light activated and light-activated small molecules. The Company is actively working on in-vitro, and in the near future, in-vivo HSV preclinical models to finalize a formulation for optimal dermal penetration to increase patient safety and efficacy. Good Laboratory Practice ('GLP') toxicology studies will commence once a formulation has been finalized. Additional details will be announced as strategic objectives are achieved.
Phase II Bladder Cancer Study Update ('Study II')
Interim Clinical Results
For the primary endpoint of Study II (Complete Response ('CR') at any point in time) 62% of patients provided the Study Procedure (Study Drug activated by the Study Device) demonstrated a CR. Including patients, who demonstrated an Indeterminate Response ('IR') (negative cystoscopy and positive or suspicious urine cytology), the Total Response ('TR') increases to 70%.
This represents that approximately 2 out of 3 BCG-Unresponsive NMIBC CIS patients treated with Theralase®'s unique Study Procedure are demonstrating complete destruction of their bladder cancer.
For the secondary endpoint of Study II (duration of CR) 42% of treated patients who achieved a CR, maintained their CR response for at least 12 months (450 days from date of Study Procedure).
For the tertiary endpoint of Study II (safety of Study Procedure) 100% (69/69) experienced no Serious Adverse Events ('SAEs') directly related to the Study Drug or Study Device.
Outside of the defined endpoints of Study II, Theralase® has demonstrated a duration of CR at extended time points of 23% at 2 years, 21% at 3 years and 2% at 7 years.
Note: Not all patients have been assessed at these extended time points. As more clinical data is collected, the duration of CR at 2, 3 and 7 years may increase.
Theralase® is on track to complete enrollment in Study II by the summer of 2025.
This will allow the Company to report on 75 patients who have completed Study II in December 2025 and to report on all 90 patients by September 2026.
Upon follow-up of all patients, the Company plans to submit a New Drug Application ('NDA') to Health Canada and the FDA in 4Q2026, with a decision expected by the respective regulatory authorities on a marketing approval in 2027.
As Theralase® completes enrollment in Study II, it is actively searching for commercialization partners for international marketing and sales of Ruvidar®.
To this end, Theralase® is in various stages of initial and advanced discussions with international pharmaceutical companies for various geographical territories concerning:
In recent discussions with the FDA, the Company has decided that since Study II is 91% complete, the best course of action is not to pursue Break Through Designation, but to complete Study II and submit the clinical data to the FDA in a formal NDA. At the end of the meeting, the FDA made a comment that they were impressed that the interim clinical data obtained to date was able to be achieved with only one clinical treatment, in the majority of cases.
Ruvidar® has demonstrated 10 years of shelf life, strongly supporting the stability of the molecule and the ability of clinics to store the small molecule for extended periods of time.
Additional Oncology Targets
Theralase® has combined Ruvidar® with transferrin (human glycoprotein) to form Rutherrin®.
Rutherrin® is a strong candidate for the systemic treatment of recurrent, deep seated and/or progressive cancers.
Due to the limitations of using laser light to activate Rutherrin® in deep oncological targets, Theralase® plans to activate Rutherrin® with radiation therapy to increase the 'tumour's damage zone' and the effectiveness of Theralase®'s small molecule beyond the reach of light in the body.
Rutherrin®, if clinically proven, will be able to 'hunt' and 'localize' into cancer cells and when activated by radiation 'destroy' them; wherever, they may reside in the body.
The Company expects to complete Good Laboratory Practice toxicology analysis in 4Q2025 to allow commencement of a Phase 0/I/II adaptive clinical study in 1Q2026 for the following indications:
1) Glio Blastoma Multiforme ('GBM') Brain Cancer Treatment
2) Non-Small Cell Lung Cancer ('NSCLC') Treatment
3) Pancreatic Cancer
4) Colorectal Cancer
5) Muscle Invasive Bladder Cancer ('MIBC') Treatment
6) Herpes Simplex Virus ('HSV-1") Topical Treatment for Cold Sore Lesions
For additional information, please refer to the Company's Management's Discussion and Analysis ('MD&A') available at www.sedarplus.ca.
About Ruvidar®:
Ruvidar®(TLD-1433) is a small molecule, able to be activated by light, radiation, sound and/or other drugs, intended for the safe and effective destruction of various cancers, bacteria and viruses.
About Theralase® Technologies Inc.:
Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses.
Additional information is available at www.theralase.com and www.sedarplus.ca
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements:
This news release contains Forward-Looking Statements ('FLS') within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words 'may, 'should', 'will', 'anticipates', 'believes', 'plans', 'expects', 'estimate', 'potential for' and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals.
These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company's small molecule and drug formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict.
Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS.All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS.
For investor information on the Company, please feel to reach outInvestor Inquiries - Theralase Technologies.
For More Information:
1.866.THE.LASE (843-5273)
416.699.LASE (5273)
www.theralase.com
Kristina Hachey, CPA
Chief Financial Officer X 224
[email protected]
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/253913

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Boyd Gaming (NYSE:BYD) Delivers Impressive Q2
Gaming and hospitality company Boyd Gaming (NYSE:BYD) beat Wall Street's revenue expectations in Q2 CY2025, with sales up 6.9% year on year to $1.03 billion. Its non-GAAP profit of $1.87 per share was 12.2% above analysts' consensus estimates. Is now the time to buy Boyd Gaming? Find out in our full research report. Boyd Gaming (BYD) Q2 CY2025 Highlights: Revenue: $1.03 billion vs analyst estimates of $980.9 million (6.9% year-on-year growth, 5.4% beat) Adjusted EPS: $1.87 vs analyst estimates of $1.67 (12.2% beat) Adjusted EBITDA: $329.4 million vs analyst estimates of $315.5 million (31.9% margin, 4.4% beat) Operating Margin: 23.4%, in line with the same quarter last year Market Capitalization: $6.8 billion Keith Smith, President and Chief Executive Officer of Boyd Gaming, said: "Our Company delivered a strong performance in the second quarter, with broad-based growth across our operating segments, including our Online and Managed segments. We achieved our strongest property-level revenue and Adjusted EBITDAR growth in more than three years, with property-level margins once again exceeding 40%. This growth was supported by continued strength in play from our core customers, as well as improvements in retail play. Looking ahead, the recently announced transaction to sell our equity stake in FanDuel will further strengthen the Company's financial position as we continue to invest in our properties, pursue growth opportunities, return capital to shareholders and maintain a strong balance sheet – a strategy that continues to drive long-term shareholder value." Company Overview Run by the Boyd family, Boyd Gaming (NYSE:BYD) is a diversified operator of gaming entertainment properties across the United States, offering casino games, hotel accommodations, and dining. Revenue Growth A company's long-term sales performance is one signal of its overall quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Over the last five years, Boyd Gaming grew its sales at a tepid 9.6% compounded annual growth rate. This was below our standard for the consumer discretionary sector and is a poor baseline for our analysis. We at StockStory place the most emphasis on long-term growth, but within consumer discretionary, a stretched historical view may miss a company riding a successful new product or trend. Boyd Gaming's recent performance shows its demand has slowed as its annualized revenue growth of 4.6% over the last two years was below its five-year trend. Note that COVID hurt Boyd Gaming's business in 2020 and part of 2021, and it bounced back in a big way thereafter. We can better understand the company's revenue dynamics by analyzing its most important segments, Gaming and Non-Gaming, which are 64.9% and 16.7% of revenue. Over the last two years, Boyd Gaming's Gaming revenue (casino games) was flat while its Non-Gaming revenue (hotel, food, beverage) averaged 10.2% year-on-year growth. This quarter, Boyd Gaming reported year-on-year revenue growth of 6.9%, and its $1.03 billion of revenue exceeded Wall Street's estimates by 5.4%. Looking ahead, sell-side analysts expect revenue to decline by 4.3% over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and indicates its products and services will face some demand challenges. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Operating Margin Boyd Gaming's operating margin has risen over the last 12 months and averaged 22.3% over the last two years. On top of that, its profitability was elite for a consumer discretionary business thanks to its efficient cost structure and economies of scale. This quarter, Boyd Gaming generated an operating margin profit margin of 23.4%, in line with the same quarter last year. This indicates the company's overall cost structure has been relatively stable. Earnings Per Share We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company's growth is profitable. Boyd Gaming's full-year EPS flipped from negative to positive over the last five years. This is encouraging and shows it's at a critical moment in its life. In Q2, Boyd Gaming reported EPS at $1.87, up from $1.58 in the same quarter last year. This print easily cleared analysts' estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Boyd Gaming's full-year EPS of $6.97 to shrink by 4.6%. Key Takeaways from Boyd Gaming's Q2 Results We enjoyed seeing Boyd Gaming beat analysts' revenue expectations this quarter. We were also happy its EPS outperformed Wall Street's estimates. On the other hand, its Gaming revenue missed. Overall, we think this was a solid quarter with some key areas of upside. The stock traded up 1.6% to $83.85 immediately after reporting. Boyd Gaming put up rock-solid earnings, but one quarter doesn't necessarily make the stock a buy. Let's see if this is a good investment. When making that decision, it's important to consider its valuation, business qualities, as well as what has happened in the latest quarter. We cover that in our actionable full research report which you can read here, it's free.
Yahoo
an hour ago
- Yahoo
TFSA Fortune: How 1 Technology Stock Could Secure Your Financial Future
Written by Brian Paradza, CFA at The Motley Fool Canada Imagine turning a $7,000 investment into a staggering $2.5 million position, entirely within the tax-free haven of your TFSA. That's the remarkable reality for investors in Constellation Software (TSX:CSU) stock over the past two decades – a mind-boggling total return exceeding 36,000%. While replicating that exact feat might be a tall order, a spun-off company following the same powerful blueprint strategy could be poised for significant long-term growth, making it a compelling candidate for your own TFSA. That TSX technology stock is (TSXV:TOI), and it's grabbing serious attention this week as the top performer on the TSX's Top Tech 50 list. isn't just riding a growth wave; it's actively building one. Much like its former parent Constellation Software, Topicus focuses on acquiring, managing, and building specialized vertical market software businesses – essential software solutions tailored for specific industries. While Constellation conquered North America, is methodically applying the same winning strategy across diverse markets in Europe. Canadian investors seeking long-term growth within their TFSA may find Topicus's focused approach appealing. Why stock deserves a place in your TFSA The tech stock's early results are promising. spun off from Constellation in early 2021, and early investors are already sitting on gains nearing 200%. More importantly, the underlying business is firing on all cylinders. first-quarter 2025 results showcased impressive momentum. Revenue surged 16% year-over-year to €355.6 million (about $569 million CAD), driven by strategic acquisitions and a solid 4% organic growth rate. Earnings per share jumped an even more impressive 36.4% to €0.30. But the real story, the fuel powering growth engine, is its free cash flow (FCF). This crucial metric represents the cash a company generates after accounting for operating expenses and capital expenditures — the actual cash-based profit available for reinvestment, dividends, or debt repayment. Topicus generated a staggering €271.4 million in cash flow from operations during the first quarter, leading to free cash flow of €161.7 million ($258.8 million CAD), a 21% year-over-year increase. This torrent of free cash flow is the lifeblood of growth strategy. It allows the TSX tech stock to aggressively pursue acquisitions without constantly needing external financing. For example, during the first quarter, completed acquisitions totaling €39.4 million ($63 million CAD). With quarterly FCF exceeding €161 million, Topicus has the capacity to significantly ramp up its deal-making. It could could have quadrupled its acquisition spend just from the first quarter FCF alone! This self-sustaining model is precisely how Constellation built its empire. Long-term oriented TFSA investors may wish to check stock out before fully deploying their $7,000 contribution room for 2025. TOI stock valuation and the Constellation blueprint To be clear, TOI stock carries a premium valuation. Its forward price-to-earnings ratio (P/E) sits around 69, higher than the industry average of 52. However, looking solely at earnings misses the bigger picture fueled by cash. When you consider its phenomenal cash generation, stock looks far more reasonably priced. Its price-to-free-cash-flow (P/FCF) multiple is 38.6, significantly cheaper than the North American industry average of 66. Similarly, its enterprise value-to-free-cash-flow (EV/FCF) multiple of 25 compares very favourably to the industry average of 56. The big question for TFSA investors is: Can replicate the phenomenal success of Constellation Software stock? ^TSX data by YCharts The potential for stock to widely outperform the TSX is certainly there. Topicus still operates under Constellation's guidance, and it is using the exact same proven playbook. The company's core strategy of acquiring essential, niche software businesses is time-tested. Chances of outright failure seem low. However, tempering expectations is prudent. Europe presents different market dynamics than North America. More crucially, the timing is different. Constellation began its acquisition spree 30 years ago in 1995 and survived the aftermath of the dot-com bust, finding bargains when tech valuations were depressed. Topicus is executing its strategy in the artificial intelligence (AI) era, where software valuations are generally higher. While the strategy is sound, expecting an identical 36,000% return over the next 20 years is potentially unrealistic. TFSA investor takeaway stock represents a fascinating opportunity for TFSA investors seeking long-term, tax-free compound growth. It possesses a powerful engine: the proven Constellation Software acquisition strategy, now focused on the European market, and fueled by rapidly growing, substantial free cash flow. This internally generated cash allows the technology stock to aggressively fund its own growth, creating a potentially powerful compounding effect within your TFSA. The post TFSA Fortune: How 1 Technology Stock Could Secure Your Financial Future appeared first on The Motley Fool Canada. Should you invest $1,000 in Constellation Software right now? Before you buy stock in Constellation Software, consider this: The Motley Fool Stock Advisor Canada analyst team just identified what they believe are the Top Stocks for 2025 and Beyond for investors to buy now… and Constellation Software wasn't one of them. The Top Stocks that made the cut could potentially produce monster returns in the coming years. Consider MercadoLibre, which we first recommended on January 8, 2014 ... if you invested $1,000 in the 'eBay of Latin America' at the time of our recommendation, you'd have $24,927.94!* Stock Advisor Canada provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month – one from Canada and one from the U.S. The Stock Advisor Canada service has outperformed the return of S&P/TSX Composite Index by 30 percentage points since 2013*. See the Top Stocks * Returns as of 6/23/25 More reading 10 Stocks Every Canadian Should Own in 2025 3 Canadian Companies Powering the AI Revolution A Commonsense Cash Back Credit Card We Love Fool contributor Brian Paradza has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends The Motley Fool recommends Constellation Software. The Motley Fool has a disclosure policy. 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Wire
an hour ago
- Business Wire
The Clover x Shark Tank Summit Reveals Full Speaker Line-Up and Programming for First-Ever Live Event in Las Vegas from September 28-30
LAS VEGAS--(BUSINESS WIRE)--Today, Clover, the world's smartest all-in-one point-of-sale system, and Sony Pictures Television (SPT), which produces the critically acclaimed, multi-Emmy® Award-winning 'Shark Tank,' announced the full speaker line-up and programming for the first-ever live, Clover x Shark Tank Summit. Taking place in Las Vegas from September 28-30, 2025, the multi-day event will provide entrepreneurs with inspiration, in-depth insights, and the guidance they need to find success. The Clover x Shark Tank Summit is sponsored by ADP® and in partnership with media partner, Inc., the leading media brand and playbook for entrepreneurs and business leaders shaping our future. This year's Clover x Shark Tank Summit will feature previously announced business tycoons – the 'Sharks' from the hit reality TV show, including Barbara Corcoran, Robert Herjavec, Daymond John, Kevin O'Leary, Daniel Lubetzky and two exciting guest Sharks, Rashaun Williams, venture capitalist and financial literacy activist, and Allison Ellsworth, co-founder of poppi, who recently sold poppi for close to $2B. Additional notable speakers include Mark Cuban, Tabitha Brown and Gary Vaynerchuck. The lineup will also include world famous entrepreneurs, dealmakers, brand builders, company founders, and more, who will speak on all things small business, including raising capital, community, mastering your business pitch, talent trends, marketing, and much more. Newly announced to the star-studded line-up of speakers from 'Shark Tank' are Emmy®-nominated Mindy Zemrak, Supervising Casting Producer of 'Shark Tank,' Jim Tselikis and Sabin Lomac, co-founders of Cousins Maine Lobster, and one of Barbara's Corcoran's most popular and successful 'Shark Tank' investments, David Heath and Randy Goldberg, co-founders of Bombas, the most successful 'Shark Tank' company in retail sales. Additional prominent speakers from the world of business are Jay Bailey, President and CEO of Russell Innovation Center for Entrepreneurs, Katie Kirkpatrick, President & CEO of Metro Atlanta Chamber, TJ Bennett, Co-owner and CEO of Sole Play, Alison Lands and Khalilah 'KO' Olokunola of Jobs For The Future, Mike Hofman, Editor-in-Chief of Inc., Melissa Bouma, CEO of Manifest and Jess Sims, Peloton Instructor, ESPN Reporter & GMA Contributor. Throughout the three-day event, attendees will gain insights from experts and take a deep dive into what it takes to start, grow and scale a business ranging from sessions such as: Shark-Sized Confidence: Invest in You – a powerful fireside chat on investing in yourself, self-care, resilience, and staying grounded while you grow. – a powerful fireside chat on investing in yourself, self-care, resilience, and staying grounded while you grow. The Big Catch: Raising Capital with a Shark Tank Mindset – learn how to think beyond the bank with nontraditional funding routes to raising capital that still pack power. – learn how to think beyond the bank with nontraditional funding routes to raising capital that still pack power. Swim With Your Pack: Why Community is Your Strategic Advantage – a powerhouse session on how innovation, leadership, and public-private partnerships can fuel businesses that move communities forward. – a powerhouse session on how innovation, leadership, and public-private partnerships can fuel businesses that move communities forward. For That Reason, I'm In: Master the Pitch – an interactive workshop to help you master the art of the pitch, from funding fundamentals to real-time demos, these tips will help you win over investors, banks, and more. – an interactive workshop to help you master the art of the pitch, from funding fundamentals to real-time demos, these tips will help you win over investors, banks, and more. Think Like a Shark: From Scrappy to Scalab l e —Your Zero to Hero Game Plan – a high-powered session covering the 10 must-dos before raising capital, plus insider tips on VC funds and more. l —Your Zero to Hero Game Plan – a high-powered session covering the 10 must-dos before raising capital, plus insider tips on VC funds and more. Make Them Bite: Branding that Grows Your Business – a powerhouse panel on the new rules of branding and marketing, delivering strategies entrepreneurs can use to grow their business. – a powerhouse panel on the new rules of branding and marketing, delivering strategies entrepreneurs can use to grow their business. Catch the Best: How to Net Top Talent – an in-depth view on how to hire, inspire, and retain top talent. – an in-depth view on how to hire, inspire, and retain top talent. The Final Pitch – The conference culminates in an exciting celebratory moment when a select group of entrepreneurs will take to the stage to pitch live before an audience and a distinguished panel – including Sharks! Ahead of the Clover x Shark Tank Summit, small business owners can enter to win an Access Pass for a chance to participate in the event. The entry period runs through August 11. Entrepreneurs looking to elevate their businesses can visit for complete details. To learn more about Clover and how the brand is providing solutions for small businesses, including the Clover x Shark Tank Summit, visit and follow @clovercommerce on Instagram, X, Facebook, and LinkedIn with hashtag #CloverxSharkTankSummit. Since launching in 2001 as 'Money Tigers' on Nippon TV in Japan and known around the world under titles including 'Dragons' Den,' 'Shark Tank,' and 'Lions' Den,' the Sony Pictures Television-distributed format has become the world's number one adapted business reality television show, in terms of the number of territories launched. Produced in territories on every continent, the format sees aspiring entrepreneurs pitch to secure investment from some of the top names in the business world. About Fiserv Fiserv, Inc. (NYSE: FI), a Fortune 500 company, moves more than money. As a global leader in payments and financial technology, the company helps clients achieve best-in-class results through a commitment to innovation and excellence in areas including account processing and digital banking solutions; card issuer processing and network services; payments; e-commerce; merchant acquiring and processing; and Clover®, the world's smartest point-of-sale system and business management platform. Fiserv is a member of the S&P 500® Index and one of Fortune® World's Most Admired Companies™. Visit and follow on social media for more information and the latest company news. About Shark Tank The recipient of five Emmy Awards for Outstanding Structured Reality Program, ABC's 'Shark Tank,' premiering its 17th season this fall, features the Sharks – tough, self-made, multimillionaire and billionaire tycoons – as they invest in America's best businesses and products. The Sharks give people from all walks of life the chance to chase the American Dream and potentially secure life-changing business deals. The Sharks are real estate mogul Barbara Corcoran; prolific CPG investor and self-made inventor of retail products Lori Greiner; cyber-security technology innovator Robert Herjavec; fashion and branding expert Daymond John; venture capitalist Kevin O'Leary; and philanthropist and founder of KIND Snacks and the Builders, Daniel Lubetzky. Mark Burnett, Clay Newbill, Yun Lingner, Max Swedlow, Brandon Wallace, Barbara Corcoran, Lori Greiner, Robert Herjavec, Daymond John, Kevin O'Leary, Barry Poznick, and Phil Gurin are the executive producers of 'Shark Tank,' which is based on the Japanese 'Dragons' Den' format, created by Nippon TV. The series is produced by MGM Television, a division of Amazon MGM Studios, in association with Sony Pictures Television. About Sony Pictures Television Sony Pictures Television (SPT) is one of the television industry's leading content providers, producing, distributing and carrying programming worldwide in every genre and for every platform. In addition to managing one of the industry's largest libraries of award-winning feature films, television shows and formats, SPT is home to a thriving global content business, operating a robust portfolio of wholly-owned and joint-venture production companies across the U.S., Europe, Latin America, and Asia Pacific, as well as linear and digital channels around the world. SPT is a Sony Pictures Entertainment Company, a subsidiary of Tokyo-based Sony Group Corporation. FI-G